Market Overview

JP Morgan: BioLineRx Will Outperform, Is Worth $5/Share On 'Promising Technology'


In a report published Monday, JPMorgan analysts initiated coverage of Bioline RX Ltd (NASDAQ: BLRX) with an Outperform rating and $5 price target.

"BioLine RX is advancing an arsenal of products in development with the hope of delivering important new therapies to treat a wide variety of diseases," the analysts stated, while adding, "[W]e believe investors are undervaluing the pipeline potential of BLRX, considering that four of its six clinical assets are in Phase II trials or have efficacy validity data, with estimated worldwide sales potential of over $3.7bn."

The company's strategy is to rapidly build value for its early stage pre-clinical assets "in a capital efficient manner," and then move them forward to clinically derisking the technology. This would help BioLine RX to attract a pharma partner, who would invest in the later-stage development and commercialization of its products.

"BLRX is currently at a stage where the components of this strategy are in place, with potential for exponential growth," the JP Morgan report added.

Latest Ratings for BLRX

Aug 2017Initiates Coverage OnOutperform
May 2017UpgradesHoldBuy
Feb 2017Initiates Coverage OnBuy

View More Analyst Ratings for BLRX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings


Related Articles (BLRX)

View Comments and Join the Discussion!

Latest Ratings

PLANEvercore ISI GroupUpgrades
CRYOppenheimerInitiates Coverage On34.0
ARIJP MorganDowngrades18.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Merrill Lynch Posts North America Treasurer Report

Concerned About The Keuring Kold Launch? Here's What Investors Should Know